{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:39:49Z","timestamp":1788997189814,"version":"build-2803163510"},"reference-count":16,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi231624-4\"><jats:title>Importance<\/jats:title><jats:p>Valuable evidence regarding clinical characteristics, treatments, and outcomes for non\u2013small cell lung cancer (NSCLC) is limited to individual hospital databases or national-level registries. The common data and federated analysis framework developed through the Extensible Platform for Observational Research in Lung Cancer (EXPLORE-LC) initiative allows for research across multiple high-quality data sources, which may provide a deeper understanding of the NSCLC landscape and identification of unmet needs of subpopulations.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi231624-5\"><jats:title>Objective<\/jats:title><jats:p>To describe clinical characteristics, initial treatment patterns, subsequent treatment, and overall survival (OS) of patients with NSCLC in South Korea.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi231624-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This multicenter cohort study included patients aged 18 years and older who were diagnosed with NSCLC between 2014 and 2019 and followed up until March 2020 at 3 tertiary hospitals in South Korea. Clinical data were collected using a common data model and clinical data warehouse. Patients who had an initial diagnosis of nonsquamous (NSQ) or squamous (SQ) NSCLC and who had received at least 1 treatment for NSCLC were included in the study. Data were analyzed from June through November 2022.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi231624-7\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary outcome was clinical OS for patients with NSCLC. Secondary outcomes were clinical characteristics and treatment patterns subsequent to the diagnosis of NSCLC.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi231624-8\"><jats:title>Results<\/jats:title><jats:p>Among 22\u202f101 patients with NSCLC who received anticancer treatment analyzed in this study, 17\u202f350 patients (78.5%) had NSQ and 4751 patients (21.5%) had SQ NSCLC. Clinical characteristics and outcomes and treatment patterns were assessed for 13\u202f084 patients with NSQ cancer who had known <jats:italic>EGFR<\/jats:italic> and <jats:italic>ALK<\/jats:italic> status (75.4%; mean [SD] 62.2 [10.5] years; 6552 males [50.1%]) and all 4751 patients with SQ cancer (mean [SD] age, 67.1 [8.6] years; 4427 males [93.2%]). More than half of patients with NSQ cancer were never smokers (7399 patients [56.6%]). Patients with SQ cancer were mostly males and former or current smokers (4235 patients [89.1%]) and were diagnosed at a later clinical stage than patients with NSQ cancer (eg, stage I: 1165 patients [24.5%] vs 5388 patients [41.2%]). Patients with <jats:italic>EGFR<\/jats:italic>-positive and <jats:italic>ALK<\/jats:italic>-positive NSQ cancer diagnosed between 2017 and 2019 had better median OS than similar patients diagnosed between 2014 and 2016 (<jats:italic>EGFR<\/jats:italic>-positive: not reached [95% CI, 35.9 months to not reached] vs 28.4 months [95% CI, 25.8 to 30.0 months]; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001; <jats:italic>ALK<\/jats:italic>-positive: not reached [95% CI, not reached] vs 49.5 months [95% CI, 35.1 months to not reached]; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001). No significant difference was observed in OS from first-line treatment for patients with SQ cancer.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zoi231624-9\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>This study, which pooled medical data from multiple clinical data warehouses to produce a large study cohort, may provide meaningful insights into the clinical practice of NSCLC and underscores the value of a common data model approach. The analyzable dataset may hold great promise for future comprehensive identification of subpopulations and unmet needs.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.55331","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T16:32:10Z","timestamp":1707496330000},"page":"e2355331","source":"Crossref","is-referenced-by-count":17,"title":["Epidemiology and Outcomes of Non\u2013Small Cell Lung Cancer in South Korea"],"prefix":"10.1001","volume":"7","author":[{"given":"Hyun Ae","family":"Jung","sequence":"first","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Ho","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Min","family":"Lim","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeyeon","family":"Yu","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinkyo","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DongKyu","family":"Kim","sequence":"additional","affiliation":[{"name":"Real-World Evidence Team, ALYND, Yonsei University Health System, Seoul, South Korea"},{"name":"Department of Family Medicine, Yonsei University College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu-pyo","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyehyun","family":"Jeong","sequence":"additional","affiliation":[{"name":"Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haewon","family":"Doh","sequence":"additional","affiliation":[{"name":"Real-World Evidence Team, ALYND, Yonsei University Health System, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subin","family":"Lim","sequence":"additional","affiliation":[{"name":"Real-World Evidence Team, ALYND, Yonsei University Health System, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joohyun","family":"Kim","sequence":"additional","affiliation":[{"name":"IQVIA Solutions, Real World Solutions\u2013Korea, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiahong","family":"Zhao","sequence":"additional","affiliation":[{"name":"IQVIA Solutions, Real World Solutions\u2013Asia Pacific, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Horsburgh","sequence":"additional","affiliation":[{"name":"IQVIA Solutions, Real World Solutions\u2013Asia Pacific, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dony","family":"Patel","sequence":"additional","affiliation":[{"name":"IQVIA Solutions, Real World Solutions\u2013Global, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Ae","family":"Kim","sequence":"additional","affiliation":[{"name":"IQVIA Solutions, Real World Solutions\u2013Korea, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kong Chian","family":"Toh","sequence":"additional","affiliation":[{"name":"IQVIA Solutions, Real World Solutions\u2013Asia Pacific, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,2,9]]},"reference":[{"issue":"3","key":"zoi231624r1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.v71.3","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"zoi231624r3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jtho.2021.08.011","article-title":"Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic NSCLC: updated 5-year survival rates and genomic analysis.","volume":"17","author":"Planchard","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"28","key":"zoi231624r4","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1200\/JCO.19.00934","article-title":"Five-year overall survival for patients with advanced non\u2013small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study.","volume":"37","author":"Garon","year":"2019","journal-title":"J Clin Oncol"},{"issue":"12","key":"zoi231624r5","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.21037\/tlcr","article-title":"Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea.","volume":"10","author":"Lee","year":"2021","journal-title":"Transl Lung Cancer Res"},{"issue":"Supplement 2","key":"zoi231624r7","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1016\/j.annonc.2022.02.059","article-title":"50P clinical characteristics, treatment patterns and outcomes of EGFR exon 20 insertion and other EGFR mutations in Korean aNSCLC patients.","volume":"33","author":"Yoon","year":"2022","journal-title":"Ann Oncol"},{"key":"zoi231624r8","doi-asserted-by":"publisher","first-page":"S1578","DOI":"10.1016\/j.annonc.2022.10.387","article-title":"349P EXPLORE-LC: a multi-site real-world evidence research platform for non-small cell lung cancer in Asia-Pacific.","volume":"33","author":"Toh","year":"2022","journal-title":"Ann Oncol"},{"issue":"1-2","key":"zoi231624r12","doi-asserted-by":"publisher","DOI":"10.5324\/nje.v29i1-2.4053","article-title":"A common data model for harmonization in the Nordic Pregnancy Drug Safety Studies (NorPreSS).","volume":"29","author":"Cohen","year":"2021","journal-title":"Nor Epidemiol"},{"issue":"2","key":"zoi231624r13","doi-asserted-by":"publisher","first-page":"118","DOI":"10.4046\/trd.2017.0128","article-title":"Clinical characteristics and prognostic factors of lung cancer in Korea: a pilot study of data from the Korean Nationwide Lung Cancer Registry.","volume":"82","author":"Kim","year":"2019","journal-title":"Tuberc Respir Dis (Seoul)"},{"issue":"2","key":"zoi231624r14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.4046\/trd.2020.0134","article-title":"Recent trends of lung cancer in Korea.","volume":"84","author":"Lee","year":"2021","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"zoi231624r15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.lungcan.2020.05.033","article-title":"Ten-year patient journey of stage III non-small cell lung cancer patients: a single-center, observational, retrospective study in Korea (Realtime Automatically Updated Data Warehouse in Health Care; UNIVERSE-ROOT study).","volume":"146","author":"Jung","year":"2020","journal-title":"Lung Cancer"},{"issue":"3","key":"zoi231624r16","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.jtho.2019.10.022","article-title":"Asian Thoracic Oncology Research Group expert consensus statement on optimal management of stage III NSCLC.","volume":"15","author":"Tan","year":"2020","journal-title":"J Thorac Oncol"},{"key":"zoi231624r2","unstructured":"International Agency for Research on Cancer. Cancer today. Accessed December 11, 2022. https:\/\/gco.iarc.fr\/today"},{"key":"zoi231624r6","unstructured":"Ettinger? DS, Wood? DE, Aisner? DL. Non\u2013small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. National Comprehensive Cancer Network. Accessed January 16, 2024. https:\/\/jnccn.org\/view\/journals\/jnccn\/20\/5\/article-p497.xml"},{"key":"zoi231624r9","unstructured":"Samsung Medical Center. Facts & statistics. Accessed December 11, 2022. https:\/\/www.samsunghospital.com\/gb\/language\/english\/about\/statistics.do"},{"key":"zoi231624r10","unstructured":"Asan Medical Center. Accessed December 11, 2022. http:\/\/eng.amc.seoul.kr"},{"key":"zoi231624r11","unstructured":"Observational Health Data Sciences and Informatics. The book of OHDSI: observational health data sciences and informatics. Accessed December 11, 2022. https:\/\/ohdsi.github.io\/TheBookOfOhdsi\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2814869\/jung_2024_oi_231624_1706809705.84068.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T16:32:15Z","timestamp":1707496335000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2814869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,9]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,5]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.55331","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,9]]}}}